Indian generic weight loss drug revenue will fall below $1B by Q1 2027
Resolves: Total revenue for Indian generic weight loss drugs (across all major manufacturers) is reported below $1 billion for the quarter ending March 31, 2027.
user-generated· earnings
Indian generic weight loss drug revenue will fall below $1B by Q1 2027
Market overview
The Indian generic weight loss drug market experienced a sharp spike in early 2026 due to new entrants and regulatory approvals. Revenue growth has since decelerated as demand normalization sets in.
earnings prediction market
- Implied probability (Yes)
- 75%
- Closes
- 2027-03-31
About this prediction
Resolution criteria
Total revenue for Indian generic weight loss drugs (across all major manufacturers) is reported below $1 billion for the quarter ending March 31, 2027.
Source: user-generated
More earnings markets
- Will cash burn exceed $5M in Q4? — 65% Yes
- Will Venyra beat Q4 2026 revenue consensus of $230M? — 85% Yes
- Will Nuburu secure emergency financing by Q3 end? — 35% Yes
- Will Everpure, Inc. report a non-GAAP EPS beat for the quarter ended June 30, 2026? — 50% Yes
- Will KR miss Q4 operating margin guidance? — 65% Yes
- Will George Risk report Q4 2026 revenue above $13M? — 85% Yes
- Will DCI beat Q4 EPS consensus of $0.88? — 65% Yes
- Will inventory days decrease below 70 by year-end? — 40% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…